Trevi Therapeutics Inc (NASDAQ:TRVI) shares traded 10.59% higher at $6.58 on Wall Street last session.
TRVI stock price is now 4.63% away from the 50-day moving average and 51.27% away from the 200-day moving average. The market capitalization of the company currently stands at $669.48M.
With the price target of $21, H.C. Wainwright recently initiated with Buy rating for Trevi Therapeutics Inc (NASDAQ: TRVI). On March 10, 2025, Raymond James Upgraded its previous ‘Outperform’ rating to ‘Strong Buy’ on the stock increasing its target price from $9 to quote $29, while ‘Needham’ rates the stock as ‘Buy’
In other news, SCIASCIA THOMAS, Chief Scientific Officer sold 2,631 shares of the company’s stock on Mar 25 ’25. The stock was sold for $17,365 at an average price of $6.60. Upon completion of the transaction, the Chief Scientific Officer now directly owns 221,373 shares in the company, valued at $1.46 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 21 ’25, President & CEO GOOD JENNIFER L sold 5,263 shares of the business’s stock. A total of $34,625 was realized by selling the stock at an average price of $6.58. This leaves the insider owning 213,313 shares of the company worth $1.4 million. A total of 41.36% of the company’s stock is owned by insiders.
During the past 12 months, Trevi Therapeutics Inc has had a low of $2.30 and a high of $7.48. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 15.38, and a quick ratio of 15.38. The fifty day moving average price for TRVI is $6.2889 and a two-hundred day moving average price translates $4.349775 for the stock.
The latest earnings results from Trevi Therapeutics Inc (NASDAQ: TRVI) was released for 2025-03-31.
